Physician profile
Michael J Chaskes
NPI 1215971395
$63,245.77
in general payments reported to CMS, 2019-2025
42 companies · $15K in 2025
The $15K reported for 2025 was more than what 96% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $834 · 2020: $140 · 2021: $5,959 · 2022: $22K · 2023: $5,850 · 2024: $13K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $26K · Food and Beverage: $6,563 · Travel and Lodging: $1,695.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $26,000.00 |
| Food and Beverage | $6,562.51 |
| Travel and Lodging | $1,695.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $29,318.85 | 2019-2025 | Watchman Access System, Watchman, Watchman Flx |
| Esperion Therapeutics, INC. | $24,691.25 | 2020-2023 | Nexletol |
| Impulse Dynamics (USA) INC. | $2,075.03 | 2023-2025 | Optimizer, Optimizer |
| Aop Health US, LLC | $1,020.69 | 2025 | Rapiblyk |
| E.R. Squibb & Sons, L.L.C. | $651.11 | 2019-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $569.37 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $446.83 | 2022-2025 | Verquvo |
| Edwards Lifesciences Corporation | $404.86 | 2019-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Pfizer INC. | $391.68 | 2019-2025 | |
| Amgen INC. | $383.41 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $346.39 | 2019-2025 | Farxiga |
| Novo Nordisk INC | $304.86 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $241.95 | 2019-2025 | Jardiance |
| Inspire Medical Systems, INC. | $217.84 | 2024-2025 | Inspire |
| Alnylam Pharmaceuticals INC. | $209.56 | 2024-2025 | Onpattro |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recor Medical INC | $169.07 | 2024-2025 | Paradise Ultrasound Renal Denervation System, Paradise Renal Denervation System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $163.96 | 2019-2024 | Lifevest |
| Cvrx, INC. | $137.07 | 2022-2024 | Barostim Neo System |
| Scpharmaceuticals INC. | $134.66 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $133.91 | 2019-2024 | Xarelto |
| Kiniksa Pharmaceuticals International, Plc | $133.16 | 2024 | Arcalyst |
| Abbott Laboratories | $130.66 | 2019 | |
| Irhythm Technologies, INC. | $123.58 | 2022-2024 | Zio Xt Patch, Zio Monitor |
| Kiniksa Pharmaceuticals, LTD. | $114.94 | 2022-2023 | Arcalyst |
| Janssen Scientific Affairs, LLC | $97.04 | 2022 | |
| Sanofi-Aventis U.S. LLC | $90.93 | 2019-2023 | |
| Lexicon Pharmaceuticals, INC. | $79.53 | 2023-2024 | Inpefa |
| Daiichi Sankyo INC. | $63.56 | 2022-2024 | Injectafer |
| Regeneron Healthcare Solutions, INC. | $50.95 | 2019-2025 | Evkeeza |
| Amarin Pharma, INC. | $44.53 | 2019-2021 | |
| Abiomed | $39.67 | 2024-2025 | Impella |
| Bayer Healthcare Pharmaceuticals INC. | $38.51 | 2024-2025 | |
| Gilead Sciences, INC. | $37.91 | 2022 | |
| Corcept Therapeutics | $31.58 | 2025 | Korlym |
| Bridgebio Pharma, INC. | $27.45 | 2025 | Attruby |
| Itamar Medical INC | $27.26 | 2023 | Watchpatone |
| Glaxosmithkline, LLC. | $27.22 | 2023 | Shingrix, Arexvy |
| Smith+Nephew, INC. | $17.82 | 2023 | Renasys Touch, Renasys Go V2 Home, Pico |
| Lilly USA, LLC | $15.77 | 2023 | Mounjaro, Trulicity |
| Seqirus USA INC | $15.14 | 2022 | |
| Tactile Systems Technology INC | $13.22 | 2023 | Flexitouch Plus, Entre Plus |
| Chiesi USA, INC. | $12.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Chaskes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.